Patent US4507281A successfully refreshed from Google Patents.
US4507281A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Interferon-containing compositions
Assignee: Exovir Inc
•
Filing: 1983-10-28
•
Granted: 1985-03-26
•
Expires: 2003-10-28
Abstract
Abstract A composition for treating herpes simplex viral infections in humans is disclosed, comprising about 10 2 to 10 8 I.U. of human interferon, about 0.1% to 20% by weight of an antiviral surface active agent, and a physiologically acceptable carrier. Most preferably, the composition comprises about 10 4 to 10 6 I.U. of human leukocyte interferon, about 1% to 5% by weight of a nonionic surface active agent having at least one ether or amide linkage, and a physiologically acceptable carrier. A method for treating herpes simplex viral infections in humans is also disclosed, comprising topically administering an effective amount of said antiherpetic composition to the affected area. Most preferably, an effective amount of said antiherpetic composition is topically administered to the affected area during the prodromal stage of viral multiplication.
Inventors
- 👤 Samuel S. Asculai
- 👤 Fred Rapp
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 15:23
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
28 words
A therapeutic composition for treating herpes simplex viral infections in humans, comprising an effective amount of human interferon, an effective amount of nonylphenoxypolyethoxyethanol, and a physiologically acceptable carrier.
Claim 2
Dependent Claim
28 words
A therapeutic composition for treating herpes simplex viral infections in humans, comprising an effective amount of human interferon, an effective amount of nonylphenoxypolyethoxyethanol, and a physiologically acceptable carrier.
Claim 3
Dependent Claim
21 words
A composition as in claim 1, wherein the amount of human interferon is from about 10 2 to 10 8 I.U.
Claim 4
Dependent Claim
21 words
A composition as in claim 1, wherein the amount of human interferon is from about 10 4 to 10 6 I.U.
Claim 5
Dependent Claim
22 words
A composition as in claim 1, wherein the amount of nonylphenoxypolyethoxyethanol is from about 0.1% to 20% by weight of said composition.
Claim 6
Dependent Claim
22 words
A composition as in claim 1, wherein the amount of nonylphenoxypolyethoxyethanol is from about 1% to 5% by weight of said composition.
Claim 7
Dependent Claim
13 words
A composition as in claim 1, wherein the human interferon is leukocyte interferon.
Claim 8
Dependent Claim
20 words
A composition as in claim 1, wherein the carrier comprises water, ethanol, polyethylene glycol, mineral oil, petrolatum, or propylene glycol.
Claim 9
Dependent Claim
14 words
A composition as in claim 1, wherein said carrier is a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
14 words
A composition as in claim 1, wherein said carrier is a cosmetically acceptable carrier.
Claim 11
Independent Claim
33 words
A method for treating herpes simplex viral infections in humans, comprising topically administering to an affected area an effective amount of a therapeutic composition comprising human interferon, nonylphenoxypolyethoxyethanol, and a physiologically acceptable carrier.
Claim 12
Independent Claim
33 words
A method for treating herpes simplex viral infections in humans, comprising topically administering to an affected area an effective amount of a therapeutic composition comprising human interferon, nonylphenoxypolyethoxyethanol, and a physiologically acceptable carrier.
Claim 13
Dependent Claim
21 words
A method as in claim 10, wherein the amount of human interferon is from about 10 2 to 10 8 I.U.
Claim 14
Dependent Claim
21 words
A method as in claim 10, wherein the amount of human interferon is from about 10 4 to 10 6 I.U.
Claim 15
Dependent Claim
22 words
A method as in claim 10, wherein the amount of nonylphenoxypolyethoxyethanol is from about 0.1% to 20% by weight of said composition.
Claim 16
Dependent Claim
22 words
A method as in claim 10, wherein the amount of nonylphenoxypolyethoxyethanol is from about 1% to 5% by weight of said composition.
Claim 17
Dependent Claim
14 words
A method as in claim 10, wherein said human interferon is human leukocyte interferon.
Claim 18
Dependent Claim
30 words
A method as in claim 10, wherein said therapeutic composition is topically administered to an affected area prior to the appearance of a lesion due to herpes simplex viral infection.
Claim 19
Dependent Claim
19 words
A method as in claim 10, wherein said therapeutic composition is applied to the genital area of a human.
Claim 20
Dependent Claim
19 words
A method as in claim 10, wherein said composition is applied in a foam, spray, tampon or vaginal suppository.
Claim 21
Dependent Claim
15 words
A method as in claim 10, wherein said composition is applied about every 2-4 hours.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-03-25 | 1988-09-24 | 1989-03-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-03-25 | 1992-09-24 | 1993-03-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-03-25 | 1996-09-24 | 1997-03-26 | $7700.00 | Window Closed / Lapsed |